his.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet, Stockholm, Sweden.
Vise andre og tillknytning
2019 (engelsk)Inngår i: Nature Communications, ISSN 2041-1723, E-ISSN 2041-1723, Vol. 10, nr 1, s. 1-13, artikkel-id 3081Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Dimethyl fumarate (DMF) is a first-line-treatment for relapsing-remitting multiple sclerosis (RRMS). The redox master regulator Nrf2, essential for redox balance, is a target of DMF, but its precise therapeutic mechanisms of action remain elusive. Here we show impact of DMF on circulating monocytes and T cells in a prospective longitudinal RRMS patient cohort. DMF increases the level of oxidized isoprostanes in peripheral blood. Other observed changes, including methylome and transcriptome profiles, occur in monocytes prior to T cells. Importantly, monocyte counts and monocytic ROS increase following DMF and distinguish patients with beneficial treatment-response from non-responders. A single nucleotide polymorphism in the ROS-generating NOX3 gene is associated with beneficial DMF treatment-response. Our data implicate monocyte-derived oxidative processes in autoimmune diseases and their treatment, and identify NOX3 genetic variant, monocyte counts and redox state as parameters potentially useful to inform clinical decisions on DMF therapy of RRMS.

sted, utgiver, år, opplag, sider
Nature Publishing Group, 2019. Vol. 10, nr 1, s. 1-13, artikkel-id 3081
Emneord [en]
placebo-controlled phase-3, TH17 cell-differentiation, regulatory T-cells, oxidative stress, hydrogen-peroxide, redox regulation, NRF2 pathway, oral BG-12, arthritis, suppression
HSV kategori
Forskningsprogram
Bioinformatik
Identifikatorer
URN: urn:nbn:se:his:diva-17478DOI: 10.1038/s41467-019-11139-3ISI: 000475295300003PubMedID: 31300673Scopus ID: 2-s2.0-85068978610OAI: oai:DiVA.org:his-17478DiVA, id: diva2:1338916
Tilgjengelig fra: 2019-07-25 Laget: 2019-07-25 Sist oppdatert: 2019-11-08bibliografisk kontrollert

Open Access i DiVA

fulltext(2803 kB)116 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 2803 kBChecksum SHA-512
b67eb9ea3e59d09c91019a1a68a335afeaee04a72507fdbc33a06d4aa44108b8c794bb070993fc1ddef608a4b28b2a895ecdd7b565abcbb95e485db52c90ade3
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMedScopus

Personposter BETA

Badam, Tejaswi

Søk i DiVA

Av forfatter/redaktør
Badam, Tejaswi
Av organisasjonen
I samme tidsskrift
Nature Communications

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 116 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 393 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf